(UroToday.com) The Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2021 annual meeting included a metastatic castrate-resistant prostate cancer (mCRPC) session and a presentation by Dr. Robert Flavell discussing beta-emitting PSMA molecular radiotherapy in mCRPC. Dr. Flavell notes that there is much excitement around PSMA radioligand therapy, which is a theranostic treatment strategy that leverages the success of PSMA PET imaging. There are numerous clinical trials underway, which are mainly but not exclusively revolving around 177Lu-based agents.